Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rooney

Showing results (111-120 of 165) with videos related to

Pageof 17
Sort By:
The Journal of Infectious Diseases|July 31, 2019
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in MacaquesIvana Massud, Mian-Er Cong, Susan Ruone, et al.
Open Forum Infectious Diseases|July 10, 2024
Long-acting HIV Treatments: Study Design, Logistics, and AccessNicholas A Murdock, Nayri E Alajaji, Robin Schaefer, et al.
AIDS Research and Human Retroviruses|September 20, 2021
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil FumarateIan M McGowan, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M Brand, et al.
The Journal of Infectious Diseases|June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative GroupR T Schooley, C Ramirez-Ronda, J M Lange, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 28, 2022
Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and PharmacokineticsJenell S Coleman, Clarissa P Diniz, Edward J Fuchs, et al.
The Journal of Infectious Diseases|September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final resultsPaul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 23, 2024
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083Meredith E Clement, Brett Hanscom, Daniel Haines, et al.
Annals of Internal Medicine|February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
The Lancet. HIV|December 3, 2020
Multi-stakeholder consensus on a target product profile for an HIV cureSharon R Lewin, Timothy Attoye, Cathy Bansbach, et al.
The Lancet. HIV|October 8, 2017
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trialLinda-Gail Bekker, Surita Roux, Elaine Sebastien, et al.
Pageof 17

Showing results (111-120 of 165) with videos related to

Sort By:
Pageof 17
The Journal of Infectious Diseases|July 31, 2019
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in MacaquesIvana Massud, Mian-Er Cong, Susan Ruone, et al.
Open Forum Infectious Diseases|July 10, 2024
Long-acting HIV Treatments: Study Design, Logistics, and AccessNicholas A Murdock, Nayri E Alajaji, Robin Schaefer, et al.
AIDS Research and Human Retroviruses|September 20, 2021
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil FumarateIan M McGowan, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M Brand, et al.
The Journal of Infectious Diseases|June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative GroupR T Schooley, C Ramirez-Ronda, J M Lange, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 28, 2022
Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and PharmacokineticsJenell S Coleman, Clarissa P Diniz, Edward J Fuchs, et al.
The Journal of Infectious Diseases|September 16, 2011
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final resultsPaul E Sax, Camlin Tierney, Ann C Collier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 23, 2024
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083Meredith E Clement, Brett Hanscom, Daniel Haines, et al.
Annals of Internal Medicine|February 16, 2011
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1Eric S Daar, Camlin Tierney, Margaret A Fischl, et al.
The Lancet. HIV|December 3, 2020
Multi-stakeholder consensus on a target product profile for an HIV cureSharon R Lewin, Timothy Attoye, Cathy Bansbach, et al.
The Lancet. HIV|October 8, 2017
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trialLinda-Gail Bekker, Surita Roux, Elaine Sebastien, et al.
Pageof 17